Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 173 results for copyright

  1. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

  2. Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)

    Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making

  3. Healthy start vitamins: special report on cost effectiveness (ECD5)

    Healthy start vitamins: special report on cost effectiveness

  4. Suture fixation of acute disruption of the distal tibiofibular syndesmosis (IPG521)

    Evidence-based recommendations on suture fixation of acute disruption of the distal tibiofibular syndesmosis. This involves threading a suture through a tunnel made in the bones (tibia and fibula) and tying the ends together to fix the joint.

  5. Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)

    Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making

  6. Ultrasound‑enhanced, catheter‑directed thrombolysis for deep vein thrombosis (IPG523)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for deep vein thrombosis. This involves using ultrasound waves and a drug to break up the clot.

  7. Ultrasound‑enhanced, catheter‑directed thrombolysis for pulmonary embolism (IPG524)

    Evidence-based recommendations on ultrasound enhanced catheter-directed thrombolysis for pulmonary embolism. This involves using ultrasound waves and a drug to break up the clot.

  8. Smoking: reducing and preventing tobacco use (QS82)

    This quality standard covers reducing and preventing tobacco use in adults, young people and children. It includes interventions to discourage people from taking up smoking, tobacco control strategies and smokefree policies. It is particularly relevant to local authorities, schools and colleges, employers and NHS service providers. It describes high-quality care in priority areas for improvement.

  9. Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)

    Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection

  10. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

  11. Interim methods guide for developing service guidance 2014 (PMG8)

    Interim methods guide for developing service guidance 2014

  12. Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)

    Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making

  13. Interim methods guide for developing good practice guidance (PMG15)

    Interim methods guide for developing good practice guidance

  14. Extracorporeal membrane oxygenation (ECMO) for acute heart failure in adults (IPG482)

    Evidence-based recommendations on extracorporeal membrane oxygenation (ECMO) for acute heart failure in adults. This involves using an artificial lung to oxygenate the blood outside the body.

  15. Insertion of a magnetic bead band for faecal incontinence (IPG483)

    Evidence-based recommendations on insertion of a magnetic-bead band for faecal incontinence. This involves placing a ring of magnetic beads into a tunnel made around the anus to prevent incontinence.